The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Vaccinia virus vaccines: Past, present and future
Open accessAbstract
Vaccinia virus (VACV) has been used more extensively for human immunization than any other vaccine. For almost two centuries, VACV was employed to provide cross-protection against variola virus, the causative agent of smallpox, until the disease was eradicated in the late 1970s. Since that time, continued research on VACV has produced a number of modified vaccines with improved safety profiles. Attenuation has been achieved through several strategies, including sequential passage in an alternative host, deletion of specific genes or genetic engineering of viral genes encoding immunomodulatory proteins. Some highly attenuated third- and fourth-generation VACV vaccines are now being considered for stockpiling against a possible re-introduction of smallpox through bioterrorism. Researchers have also taken advantage of the ability of the VACV genome to accommodate additional genetic material to produce novel vaccines against a wide variety of infectious agents, including a recombinant VACV encoding the rabies virus glycoprotein that is administered orally to wild animals. This review provides an in-depth examination of these successive generations of VACV vaccines, focusing on how the understanding of poxviral replication and viral gene function permits the deliberate modification of VACV immunogenicity and virulence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
(1988) · World Health Organization eBooks · Cited by 1,574
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,302
(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines
Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S., Lalor, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.020 · Cited by 601
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter, G., & Moss, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10847 · Cited by 600
Complications of Smallpox Vaccination, 1968: National Surveillance in the United States
Lane, J. M., Ruben, F. L., Neff, J. M., & Millar, J. D. (1969) · New England Journal of Medicine · doi:10.1056/nejm196911272812201 · Cited by 545
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Antoine, G., Scheiflinger, F., Dorner, F., & Falkner, F. G. (1998) · Virology · doi:10.1006/viro.1998.9123 · Cited by 507
Symons, J. A., Alcamí, A., & Smith, G. L. (1995) · Cell · doi:10.1016/0092-8674(95)90076-4 · Cited by 490
Cited by
Monkeypox: disease epidemiology, host immunity and clinical interventions
Lum, F.-M., Torres-Ruesta, A., Tay, M. Z., Lin, R. T. P., Lye, D. C., Rénia, L., & Ng, L. F. P. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00775-4 · Cited by 541
Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity
Smith, G. L., Benfield, C. T. O., Maluquer de Motes, C., Mazzon, M., Ember, S. W. J., Ferguson, B. J., & Sumner, R. P. (2013) · Journal of General Virology · doi:10.1099/vir.0.055921-0 · Cited by 364
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Tian, Y., Xie, D., & Yang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00951-x · Cited by 293
Viral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222
Comparing signals of natural selection between three Indigenous North American populations
Reynolds, A. W., Mata-Míguez, J., Miró-Herrans, A., Briggs-Cloud, M., Sylestine, A., Barajas-Olmos, F., Garcia-Ortiz, H., Rzhetskaya, M., Orozco, L., Raff, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819467116 · Cited by 67
Metadata
- Authors
- Jacobs, B. L., Langland, J. O., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S. A., Wong, S., Huynh, T., & Baskin, C. R.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 84
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2033629536
- Cited by
- 279
- References
- 82
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccinia virus vaccines: Past, present and future. https://app.cochat.ai/papers/10.1016/j.antiviral.2009.06.006
- The paper
- Jacobs, B. L., Langland, J. O., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S. A., Wong, S., Huynh, T., & Baskin, C. R. (2009). Vaccinia virus vaccines: Past, present and future. Antiviral Research. https://doi.org/10.1016/j.antiviral.2009.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.